CAR T-Cell Therapy for Relapsed/Refractory CLL
2 Vues
• 07/14/23
0
0
Intégrer
administrator
Les abonnés
The panelists provide insight on the use of chimeric antigen receptor T-cell therapy for chronic lymphocytic leukemia and the TRANSCEND CLL-004 trial of liso-cel (JCAR017) in relapsed/refractory disease.
Montre plus
Commentaires de Facebook
SORT BY-
Meilleures Commentaires
-
Derniers Commentaires